Keyword: Juluca (dolutegravir and rilpivirine)
A cabotegravir/rilpivirine combo as a monthly HIV treatment showed similar efficacy to a standard three-drug therapy.
Activists are pushing the federal government to break Gilead's Truvada patent due to access concerns.
ViiV's dolutegravir and lamivudine combo works as well as standard three-drug HIV treatment, as Juluca maintains viral suppression through 100 weeks.
Analysts hold back some optimism as they wait for the new therapy's resistance profile that has been a key question around HIV two-drug approach.
GSK execs lauded their HIV drugs Triumeq and Tivicay this week, but both fell short of forecasts—thanks to Gilead's new Biktarvy, analysts say.
GlaxoSmithKline picked up two important Shingrix nods from regulators in Europe and Japan.
Thursday was a busy day for Europe’s regulators—and their whirl of activity will send several drugmakers into the weekend happy.
Gilead released data from a clinical trial showing that its new three-med HIV combo Biktarvy is noninferior to a treatment containing three GSK drugs.
After reporting a dismal hep C sales outlook, Gilead got a boost with an FDA nod for HIV combo Biktarvy, a drug with sales estimates of up to $10B.